专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP0703989A1 COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6 失效转让
标题翻译：组合物和诊断程序使用抗CD44V6单克隆抗体
公开(公告)号：EP0703989A1
公开(公告)日：1996-04-03
申请号：EP94918396.0
申请日：1994-06-16
申请人： JALKANEN, Sirpa , SALMI, Marko
发明人： JALKANEN, Sirpa , SALMI, Marko
IPC分类号： C12N15 , A61K39 , C07K14 , C07K16 , C12P21 , C12R1
CPC分类号： C07K14/70585 , C07K16/2884 , C07K2317/34 , C07K2319/00 , Y10S436/813
摘要： Monoclonal antibody (DSM ACC1213) which binds only to forms of CD44 containing the amino acid sequence encoded by exon v6, but not to the 90 kilodalton standard lymphocyte form of CD44 and the use of such antibodies for detecting the presence of CD44v6 in tissues or cells, for determining if epithelial tissue from an animal or human has undergone malignant transformation, for determining the metastatic potential of malignant cells and for detecting inflammatory diseases in patients.

2. 发明公开

EP1463760A2 COMMON LYMPHATIC ENDOTHELIAL AND VASCULAR ENDOTHELIAL RECEPTOR-1 (CLEVER-1) AND USES THEREOF 有权转让
标题翻译： COMMON淋巴细胞性内皮细胞和血管内皮细胞受体-1（CLEVER-1）及其用途
公开(公告)号：EP1463760A2
公开(公告)日：2004-10-06
申请号：EP03729265.3
申请日：2003-01-08
申请人： JALKANEN, Sirpa , Irjala, Heikki , Salmi, Marko
发明人： JALKANEN, Sirpa , Irjala, Heikki , Salmi, Marko
IPC分类号： C07K14/705 , A61K38/17 , A61K39/395 , A61P29/00 , A61P35/04
CPC分类号： C07K14/7056 , A61K2039/505 , C07K16/28
摘要： A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.

3. 发明公开

EP0656906A1 A NOVEL ENDOTHELIAL CELL MOLECULE MEDIATING LYMPHOCYTE BINDING IN MAN 有权转让
标题翻译： NOVEL内皮分子中ENGAGED人民淋巴细胞的，绑定。
公开(公告)号：EP0656906A1
公开(公告)日：1995-06-14
申请号：EP93913035.0
申请日：1993-06-09
申请人： JALKANEN, Sirpa , SALMI, Marko
发明人： JALKANEN, Sirpa , SALMI, Marko
IPC分类号： G01N33 , A61K39 , A61P1 , A61P17 , A61P19 , A61P29 , A61P31 , A61P37 , A61P43 , C07K14 , C07K16 , C12N5 , C12N15 , C12P21 , A61K38 , C12R1
CPC分类号： C07K14/705 , A61K38/00 , C07K16/28
摘要： A novel endothelial cell molecule, VAP-1, that mediates lymphocyte binding in man, is described. Anti-VAP-1 monoclonal antibodies are described and the monoclonal antibody 1B2 is provided by this invention, as well as the hybridoma cell line (DSM ACC2041) which produces it. This invention further provides methods for the treatment of inflammatory and autoimmune diseases by the administration of VAP-1 binding compounds, such as anti-VAP-1 antibodies.

4. 发明申请

WO2014125164A1 A METHOD FOR DETERMINING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) RELATED BIOMARKERS, A METHOD TO MONITOR THE DEVELOPMENT AND TREATMENT OF ARDS IN A PATIENT 审中-公开
标题翻译：用于确定急性呼吸道综合征（ARDS）相关生物标志物的方法，监测患者中ARDS发展和治疗的方法
公开(公告)号：WO2014125164A1
公开(公告)日：2014-08-21
申请号：PCT/FI2014/050051
申请日：2014-01-22
申请人： FARON PHARMACEUTICALS OY , MAKSIMOW, Mikael , SALMI, Marko , JALKANEN, Markku , JALKANEN, Sirpa
发明人： MAKSIMOW, Mikael , SALMI, Marko , JALKANEN, Markku , JALKANEN, Sirpa
IPC分类号： G01N33/573 , G01N30/90 , C07K14/705 , C07K14/565 , C12N9/16
CPC分类号： G01N33/573 , A61K38/215 , G01N30/90 , G01N33/6884 , G01N33/6893 , G01N2333/70596 , G01N2333/916 , G01N2800/125 , G01N2800/52 , G01N2800/60
摘要： This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS. The invention concerns further a method for simultaneous determination of a multiple of biomarkers in a sample from a patient, wherein said biomarkers are related to ARDS. The level or the activity of the biomarkers is determined. The invention also concerns a diagnostic kit useful for carrying out the method, particularly a kit comprising a chip, such as a microarray suitable for use in biochip technology.
摘要翻译：本发明涉及监测患者ARDS发展和治疗ARDS的方法。用于监测ARDS发展的方法是基于将在稍后时间点绘制的样品中获得的生物标志物的水平或活性与在先前时间点绘制的样品中相同生物标志物的水平或活性进行比较。某种生物标志物的水平或活性的有利变化表示疾病的消退（患者的恢复），相反地，某种生物标志物的水平或活性的不利变化代表疾病的恶化。例如，如果所监测的一种或多种生物标志物的水平或活性停止显示有利的变化或开始显示不利的变化，则通过施用可用于治疗ARDS的治疗活性剂来增强患者的治疗。本发明还涉及用于同时测定来自患者的样品中多个生物标志物的方法，其中所述生物标志物与ARDS相关。确定生物标志物的水平或活性。本发明还涉及可用于实施该方法的诊断试剂盒，特别是包含芯片的试剂盒，例如适用于生物芯片技术的微阵列。

5. 发明申请

WO2009053523A1 A NEW BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES 审中-公开
标题翻译：用于监测疾病发展和评估治疗效果的新生物标志物
公开(公告)号：WO2009053523A1
公开(公告)日：2009-04-30
申请号：PCT/FI2008/050576
申请日：2008-10-15
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
发明人： JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
IPC分类号： G01N33/573 , C07K14/705 , C12N9/16 , G01N33/574
CPC分类号： G01N33/57484 , G01N2333/70596 , G01N2800/245 , G01N2800/324 , G01N2800/56
摘要： The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.
摘要翻译：本发明涉及用于监测患者疾病发展或用于评估患者中的细胞因子疗法或他汀类药物治疗的功效的方法，其中从所述患者抽取的组织液中的CD73用作生物标志物。本发明还涉及从个体组织液中抽出的样品中测定CD73蛋白的方法。

6. 发明申请

WO2006128951A1 COMPOSITIONS FOR TARGETING AMINE OXIDASES IN VIVO 审中-公开
标题翻译：用于在体液中靶向氨氧化物的组合物
公开(公告)号：WO2006128951A1
公开(公告)日：2006-12-07
申请号：PCT/FI2006/000144
申请日：2006-05-04
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko
发明人： JALKANEN, Sirpa , SALMI, Marko
IPC分类号： C07K7/06 , A61K38/08 , A61K47/00 , C12N9/02
CPC分类号： C07K7/06 , A61K38/08 , A61K47/64
摘要： This invention relates to a diagnostic compositions for targeting an amine oxidase enzyme in vivo, said composition comprising a labelled peptide having the capability to bind to said enzyme. Further, the invention concerns a pharmaceutical composition for use to modulate the activity of an amine oxidase enzyme, said composition comprising a peptide having the capability to bind to said enzyme, wherein said peptide further is conjugated to a therapeutically active agent. Still further, the invention concerns a novel peptide and its uses, especially as VAP-1 inhibitor.
摘要翻译：本发明涉及用于在体内靶向胺氧化酶的诊断组合物，所述组合物包含具有结合所述酶的能力的标记肽。此外，本发明涉及用于调节胺氧化酶的活性的药物组合物，所述组合物包含具有结合所述酶的能力的肽，其中所述肽进一步与治疗活性剂缀合。此外，本发明涉及新型肽及其用途，特别是作为VAP-1抑制剂。

7. 发明专利

AU2014217753A1 A method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient 未知
公开(公告)号：AU2014217753A1
公开(公告)日：2015-07-23
申请号：AU2014217753
申请日：2014-01-22
申请人： JALKANEN MARKKU , FARON PHARMACEUTICALS OY , JALKANEN SIRPA , SALMI MARKO , MAKSIMOW MIKAEL
发明人： MAKSIMOW MIKAEL , SALMI MARKO , JALKANEN MARKKU , JALKANEN SIRPA
IPC分类号： G01N33/573 , C07K14/565 , C07K14/705 , C12N9/16 , G01N30/90
摘要： This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS. The invention concerns further a method for simultaneous determination of a multiple of biomarkers in a sample from a patient, wherein said biomarkers are related to ARDS. The level or the activity of the biomarkers is determined. The invention also concerns a diagnostic kit useful for carrying out the method, particularly a kit comprising a chip, such as a microarray suitable for use in biochip technology.

8. 发明专利

AU2003201168A1 COMMON LYMPHATIC ENDOTHELIAL AND VASCULAR ENDOTHELIAL RECEPTOR-1 (CLEVER-1) AND USES THEREOF 未知
公开(公告)号：AU2003201168A1
公开(公告)日：2003-07-24
申请号：AU2003201168
申请日：2003-01-08
申请人： JALKANEN SIRPA , IRJALA HEIKKI , SALMI MARKO
发明人： JALKANEN SIRPA , IRJALA HEIKKI , SALMI MARKO
IPC分类号： G01N33/50 , A61K39/395 , A61K45/00 , A61P29/00 , A61P35/00 , A61P35/04 , A61P43/00 , C07K14/705 , C07K16/28 , C12N15/02 , C12P21/08 , C12Q1/02 , G01N33/15 , G01N33/53 , G01N33/574
摘要： A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.

9. 发明专利

FI956041A 未知
公开(公告)号：FI956041A
公开(公告)日：1996-02-06
申请号：FI956041
申请日：1995-12-15
申请人： JALKANEN SIRPA , SALMI MARKO
发明人： JALKANEN SIRPA , SALMI MARKO
IPC分类号： C07K20060101 , G01N20060101 , C07K , G01N

10. 发明专利

ZA944383B Compositions and diagnostic methods using monoclonal antibodies against CD44v6 未知
公开(公告)号：ZA944383B
公开(公告)日：1995-03-03
申请号：ZA944383
申请日：1994-06-20
申请人： JALKANEN SIRPA , SALMI MARKO
发明人： JALKANEN SIRPA , SALMI MARKO
IPC分类号： A61K39/395 , C07K14/705 , C12N15/02 , C07K16/28 , C12P21/08 , C12R1/91 , C12P , G01N
摘要： CD44 is a family of glycoproteins involved in cell-cell and cell-matrix interactions. In addition to the major 90 kD form present on most hematopoietic cells, larger forms are found on keratinocytes and carcinoma cell lines. These bigger isoforms of CD44 arise by alternative splicing that results in insertion of one or more of the "variant" exons into the extracellular part of the 90 kD constant form of the molecule. Antibodies were raised against a synthetic peptide containing a sequence encoded by the human exon 6A mAb thus obtained (designated Var3.1) strongly reacted with the plasma membranes of squamous cells in upper layers of skin and tonsil surface epithelia. Weaker staining was seen in germinal centers, vascular endothelia and enterocytes. CD44v6 was absent from tissue leukocytes and connective tissue components. In comparison, Hermes-3 epitope (on the constant part) containing forms of CD44 were preferentially localized in basal layers of epithelia, present on the surface of most leukocytes and connective tissue cells, and undetectable on the luminal surface of high endothelial venules. In benign neoplasms, epithelial cells stained with mAb Var3.1 like in normal tissues. In contrast, immunostaining of 30 squamous carcinoma specimens (both primary and metastatic lesions) revealed that malignant transformation resulted in down-regulation or disappearance of Var3.1 epitope, but in majority of cases, not in diminished expression of the Hermes-3 epitope. An examination of serum samples from normal individuals and from patients with inflammatory diseases indicated that CD44v6 was increased in samples from patients with rheumatoid arthritis or inflammatory bowel disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式